Abbott (ABT) recently received a CE Mark in Europe for the AVEIR dual chamber (DR) leadless pacemaker system, the first ever dual chamber leadless pacemaker that treats people with abnormal or slow heart rhythms. The news follows the system’s FDA approval in June last year, shortly after late-breaking clinical data revealed that the AVEIR DR system met its three prespecified primary endpoints for safety and efficacy. The latest development is expected to significantly boost the company’s Cardiac Rhythm Mana ...